Elevation of Cytotoxic Lymphocyte Gene Expression Is Predictive of Islet Allograft Rejection in Non-Human Primates
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Background. Hyperglycemia and increased insulin requirements are indicators of ongoing islet allograftrejection, but there are no reliable methods to predict or confirm rejection. Elevated expression of cytotoxic lymphocyte (CL) gene expression in peripheral blood (PB) has been reported to correlate with the occurrence of renal allograft rejection in mice and humans. This study was undertaken to determine whether upregulated expression of CL genes in the peripheral blood of non-human primate islet allograft recipients correlates with and/or is predictive of islet rejection, defined as loss of c-peptide production.
Methods. We have established quantitative PCR methods to determine the mRNA levels of the cytotoxic lymphocyte genes granzyme B, perforin, and fas ligand in blood samples from non-human primates. We have previouslydemonstrated that anti-CD154 therapy enables long-term islet allograft function in rhesus monkeys, with rejection occurring 3-9 months after the last dose of antibody. Elevation of post-prandial glucose (PPG) is indicative of rejection but occurs just prior to rejection. Four rhesus monkeys with stable graft function were given the last dose of anti-CD154 and weekly PB samples were collected, up to and after confirmation of rejection, to assess mRNA levels for CL genes.
Results. Elevation of CL gene expression preceded islet allograft rejection, defined as loss of c-peptide production, by 2.5 to 6.5 months in the four animals studied and correlated with PPG elevation in 2/4. Duration of elevated CL gene expression was 25-71 days (2 months or more for 3/4 monkeys). GB expression was the most consistent and pronounced alteration, but good correlation was obtained for all three genes.
Conclusions. Analysis of CL gene expression in PB samples may allow for detection of islet allograft rejection several months before loss of c-peptide production. The duration of elevated CL gene for a period of 1-2.5 months suggests that testing of these parameters may have practical application in clinical islet cell transplantation. Transplantation of encapsulated pancreatic islets has been proposed as a treatment for type 1 diabetes to limit rejection. Insufficient blood supply caused the loss of viability of grafted islets. The aim of our study was to evaluate the effect of vascular endothelial growth factor (VEGF) delivery (i) on angiogenesis of tissues surrounding encapsulation device, (ii) on islets survival during allo-and xenograft. 24 hours after culture, 50 pancreatic rat islets immobilized into collagen in the presence or not of VEGF (100 pg/ml) and encapsulated (AN69 membrane, HOSPAL) were implanted in the peritoneal cavity of Wistar rats (n=6) or of Swiss mice (n=6). Devices containing collagen supplemented or not with VEGF (100 pg/ml) served as controls. After 7 and 14 days of implantation, encapsulation devices and epiploic tissue surrounding the capsules were removed. Histological analysis of this tissue was performed to determine the number and the diameter of granulation tissue buds. Macrophages adhesion at the membrane surface was characterized by a phagocytosis test. Morphological aspect of encapsulated islets was studied by phase contrast microscopy and their functionality evaluated by the measure of insulin secretion in response to glucose stimulation. At each step of the study, the presence of VEGF in devices containing islets increased significantly the number of buds in rats from 39.5±3.8 to 83.3±21.2 and in mice from 18.1±5.1 to 30.5±2.3 after 7 days of implantation (p<0.001). Similar results were obtained with the buds diameter : VEGF increased significantly the buds diameter in rats (15.4±4.9 vs 5.3±2.4 mm) and in mice ( 37.41± 6.5 vs 17.18± 3.01mm) (p<0.001). Furthermore, the study of the controls revealed an increase in buds formation under the influence of VEGF alone emphasized by the presence of islets only in allogenic models. Membrane surface analysis showed a decrease in macrophage adhesion in presence of VEGF in all cases. Islets examination exhibited in presence of VEGF a preservation of their structure without central necrosis. Moreover, islets encapsulated with VEGF exhibited a preservationof their stimulation in response to glucose as compared to islets encapsulated alone. Similar results were obtained after 14 of implantation. In conclusion, VEGF delivery around the encapsulation device influence the angiogenesis of epiploic tissu and limit the cellular adhesion on the membrane together with the preservation of islet viability and functionality. Local delivery of VEGF proved to be a revelant approach to ameliorate the outcome of islets transplantation.
Effect of Vascular Endothelial Growth Factor Delivery on the Viability of Encapsulated Pancreatic Rat Islets During Allo-and Xenograft
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Cell-based therapies provide promising alternative to the treatment of numerous diseases such as insulin-dependent diabetes mellitus (IDDM) relying on the chronic administration of insulin. In this context, cell encapsulation offer an attractive solution to favor immunological acceptance of allogeneic transplanted cells and to prevent acute reactivation of the underlying auto-immune disease by insulating the implanted cells from host immune cells. ßTC-tet cells express a phenotype similar to primary pancreatic cells. They represent therefore an ideal cell model to design and test artificial devices capable of supporting ß-cell immunoisolation and in vivo cell function for the treatment of IDDM. Two encapsulation systems were investigated in parallel with these cells. Micro-encapsulation of ß-cell clusters in polylysine-alginate beads (PAB), as a non-limited diffusion model, was compared to ß-cells loading into thermoplastic polyether-sulfone flatsheet disks (PFD). Following in vitro testing, which demonstrated similar glucose responsiveness and cell survival, the two types of device were implanted intraperitoneally (IP) in streptozotocin-induced diabetic mice (blood glucose > 25 mM). PAB-encapsulated cells (2-3 × 10 6 cells) corrected glycemia (5 mM) and weight profiles within a few days to control values. The effect was observed for more then 3 months with a good cell survival on histological analysis. In contrast, PFDs (pore size < 1 mm) loaded with the same number of cells were only transiently efficient on glycemia control and showed poor cell survival. Genetic engineering of the cells with the anti-apoptotic gene bcl-2, the gluco-incretin GLP-I together with the use of more open PES membranes (pore size > 5mm) were necessary to confer a good survival and functional properties in vivo to PFD-encapsulated pure ßcells. It is concluded that non-genetically modified pure ß-cells can behave as a normal endocrine pancreas substitute only in a nonlimited diffusion microdevice system. In contrast to previous observations made with primary islets (constituted by different cell types also exerting paracrine effects, i.e. alpha-cells secreting glucagon), pure ß-cells may need, in addition to optimized oxygen supply, specific engineering to provide them with gluco-incretins in order to function properly in a macro-device configuration.
Chronic Complications of Diabetes Prevent Islet Engraftment at Three Transplantation Sites
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Reports of successful islet transplantation in humans suggest that the immunosuppressive regimen was responsible for failure of islet transplantation. Long-term follow-up of the initial transplants suggests that patients with chronic renal disease may be more likely to have failure of the intrahepatic islet allografts. We have been comparing the survival and function of islet allografts at 3 different sites of transplantation (renal subcapsular, intrahepatic, and intramuscular) in acutely diabetic (AD) rats to long-term (LT) diabetic rats with advanced chronic complications. WF rats with streptozotocin induced diabetes (blood sugars >250mg/dl) survive for at least 6 months without insulin therapy. By 6 months, the rats exhibit the advanced chronic complications of diabetes, including cataracts, muscle wasting, growth failure, renal failure, and fatty liver. Islet allografts transplanted to the renal subcapsular site in the LT animals have either primary nonfunction or graft failure by 25 days with about 60% failure in the LT rats compared to about 5% in the AD rats. About 85% of the islets allografts to the intrahepatic site in the LT rats failed by 20 days compared to 30% in AD rats without chronic complications. The intramuscular (medial thigh) allografts had all failed by 15 days compared to 10% in the AD rats. The allograft function at the intramuscular site continued to deteriorate in the AD rats after 15 days with about 60% failure by 30 days. In summary, rats with advance chronic complications of diabetes show primary nonfunction or early graft failure of islet allografts at 3 different sites oftransplantation. The mechanism of the failure is probably different at each site and is currently being investigated. The chronic complications of diabetes may provide an additional explanation for primary nonfunction or loss of islet allografts in humans.
Vascular Density in Mouse Pancreatic Islets Decreases Ater Transplantation
Goran Mattson, Leif Jansson and Per-Ola Carlsson Department of Medical Cell Biology, Uppsala University, Uppsala Sweden When pancreatic islets are isolated and cultured prior to transplantation, the islet vasculature disrupts. Although the islets are rapidly revascularized, it is uncertain whether this revascularization is sufficient. We aimed to measure pO 2 and vascular density in human islets 1 month after transplantation to athymic nude mice, and compare this to pO 2 and vascular density of native and transplanted mouse islets. The vascular density of the islet grafts was also correlated to graft blood perfusion. Tissue pO 2 was measured with Clark microelectrodes. Graft blood perfusion was measured with laser-Doppler flowmetry, and vascular density was determined following staining of histological specimens for the lectin Bandeiraea. simplicifolia (BS-1). Human islets were obtained from 7 heart-beating donors (age range 19-53) and were isolated at the Central Unit of the b-cell Transplant, Brussels, Belgium. In native mouse islets pO 2 was 404±5.0mmHg (n=6). Both the transplanted mouse and human islets had a pO 2 15-20% of that in native islets. Also the vascular density of transplanted islets was decreased compared to native islets [1.8±0.3 (n=9 mouse tx) and 2.0+0.5 (n=8, human tx) vs 3.5±0.3 (n=6, native islets) blood vessels/mm 2 ]. In contrast, a large number of blood vessels was found in connective tissue surrounding the islets in these grafts (13.0±2.6 (mouse tx) and 12.4±1.8 (human tx) blood vessels/mm2]. Graft blood perfusion was ~50% of renal cortex blood flow. When comparing donor age and blood perfusion of the human islet grafts, a strong negative correlation was found (R=0.91). A similar correlation was seen between donor age and the total vascular density of these grafts (R=0.83). However, whereas the vascular density in the stroma of the grafts also tended to correlate to donor age (11=033, P--0.06), the vascular density of the endocrine parts was not correlated at all to donor age (R=0.04). In conclusion, both transplanted mouse and human islets had a markedly decreased vascular density and pO 2 compared to endogenous mouse islets. The blood perfusion and. total vascular density of the human islet grafts negatively correlated to donor age, which could be attributed to a lower vascularization of the stroma compartment in older donors.
Protein Permeability in Biodritin (Alginate + Chondroitin Sulfate) Microcapsules for Islet Transplantation
Melina Ribeiro 1 , Camillo Ricordi 1 and Marcos Mares-Guia 2 1 Diabetes Research Institute,University of Miami, School of Medicine,Miami,FL 2 Biomm, Inc., Miami, FL Microcapsules (MC) of Biodritin, a new polymer composition described by Mares-Guia and Ricordi (US Pat Appl, 1997) , were prepared with an air-pressure generator, with diameter of 700-800 micra. In order to estimate permeability of MC to proteins, microcapsules were equilibrated, as a function of time, with buffered solutions containing proteins of known molecular weight, hydrodynamic radius and isoelectric pH, pHi. The content of polymer in the capsules, %w/v, as expected, was an important factor in restricting protein penetration. A distribution constant, Kd, was calculated as a ratio of protein concentrations inside the microcapsule and outside, in solution, after equilibrium was reached. Kd is expected to have values between 0, for full protein exclusion, and 1, when full equilibration between solution and microcapsules takes place. The results show that permeability is determined not only by the size but also, and importantly so, by the net charge on the protein. Thus, positively charged proteins of lower molecular weight, such as cytochrome c, at pH 7.4, concentrate inside the capsules and adsorb to the negatively charged polymer matrix in an ion-exchange type of process, with Kd >>1. On the other hand, negatively charged proteins, like insulin, are generally excluded from penetrating the capsules, with Kd ~ 0. Insulin, pHi <6, is also rapidly expelled from MC when included as a solute during capsule formation. The presence of encapsulated islets of Langerhans did not alter the behavior of the system. The identification of the net charge on the protein as an important factor in permeability to proteins in gels is very significant in experimental tranplantation, for it will indicate if molecules such as cytokines and chemokines will be repelled or will tend to accumulate inside the capsules over time, with favorable or unfavorable consequences for encapsulated tissues, according to which one is stored or not. Thus, members of the first group bearing positive net charge(IL-4, IL-10, IL-13, Inf gamma) may tend to accumulate inside the capsules, whereas those with negative net charges (IL-2, TNF-alpha) may be repelled. Chemokines in general will tend to accumulate in the capsules. Support: Diabetes Research Institute Foundation, USA and Biobras S.A.,Brazil. MIN6 but demonstrated the same level of expression of both 1P-10 and MCP-1 as did treated MIN6. There was no detectable expression of MIP-1a, MIP-1b or RANTES in either treated or untreated MIN6 or 2Bm. Co-treatment with L-NMMA had no effect on chemokine expression in either cell line.
Conclusions. Isolated • cells and whole-islets produce pro-inflammatory chemokines in response to cytokine treatment. The profiles of chemokine expression in P-cells and whole islets differ with whole islets expressing several additional chemokines known to originate primarily from activated leukocytes. Chemokine expression in both islets and isolated • cells is independent of NO and the NF• B signal transduction pathway. These data identify targets for therapies that may improve the efficacy of islet transplantation.
